---
figid: PMC9259985__fonc-12-877380-g005
figtitle: 'Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue'
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
organisms_ner:
- Mus musculus
- Homo sapiens
- Caenorhabditis elegans
pmcid: PMC9259985
filename: fonc-12-877380-g005.jpg
figlink: /pmc/articles/PMC9259985/figure/f5/
number: F5
caption: Mechanism of action of MAPK–targeted drugs and immunotherapies. The Ras/Raf/MEK/ERK
  signaling pathway is activated by several upstream receptor tyrosine kinases. Dabrafenib,
  vemurafenib and encorafenib are specific BRAF–inhibitors used in the treatment of
  BRAF–mutant melanoma. In a strategy to vertically target the MAPK signaling pathway,
  they are used in combination with trametinib, cobimetinib, and binimetinib respectively.
  Immune checkpoint blockade inhibits the negative regulation of T cell activation,
  thereby unleashing antitumor T–cell responses. CTLA4, cytotoxic T–lymphocyte antigen
  4; PD1, programmed cell death protein 1; PDL–1, programmed death ligand 1; RTK,
  receptor tyrosine kinase.
papertitle: 'Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue.'
reftext: Rossella Loria, et al. Front Oncol. 2022;12:877380.
year: '2022'
doi: 10.3389/fonc.2022.877380
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.
keywords: targeted-therapy | cancer therapeutics resistance | cross-resistance | sequential
  therapeutics | personalized oncology
automl_pathway: 0.9587675
figid_alias: PMC9259985__F5
figtype: Figure
redirect_from: /figures/PMC9259985__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9259985__fonc-12-877380-g005.html
  '@type': Dataset
  description: Mechanism of action of MAPK–targeted drugs and immunotherapies. The
    Ras/Raf/MEK/ERK signaling pathway is activated by several upstream receptor tyrosine
    kinases. Dabrafenib, vemurafenib and encorafenib are specific BRAF–inhibitors
    used in the treatment of BRAF–mutant melanoma. In a strategy to vertically target
    the MAPK signaling pathway, they are used in combination with trametinib, cobimetinib,
    and binimetinib respectively. Immune checkpoint blockade inhibits the negative
    regulation of T cell activation, thereby unleashing antitumor T–cell responses.
    CTLA4, cytotoxic T–lymphocyte antigen 4; PD1, programmed cell death protein 1;
    PDL–1, programmed death ligand 1; RTK, receptor tyrosine kinase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Cd274
  - Pdcd1
  - ras
  - Hras
  - Kras
  - Rem1
  - Zhx2
  - Mdk
  - Map2k1
  - Map2k2
  - Ephb2
  - Mapk1
  - Ctla4
  - CD274
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - CTLA4
  - pdl-1
  - mek-1
  - mek-2
---
